8-K: Intelligent Bio Solutions Submits FDA 510(k) for Opiate Codeine Screening

Intelligent Bio Solutions Inc. has submitted its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System to detect codeine.

Summary

• Intelligent Bio Solutions Inc. has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Intelligent Fingerprinting Drug Screening System.
• The submission seeks regulatory clearance for the system's ability to detect the opiate codeine.
• This submission is based on a comprehensive clinical program conducted throughout 2026.
• The package includes data from a Method Comparison Study showing accuracy above 98%, sensitivity above 94%, and 100% specificity.
• Other studies included Usability, Interference, Precision Testing, and Cut-off Study, all demonstrating the system's reliability and suitability for workplace deployment.
• The U.S. drug screening market is estimated to be a multi-billion dollar annual opportunity.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating significant progress towards U.S. market entry for a key product.

Positives

• Successful submission of a 510(k) premarket notification to the FDA for the Intelligent Fingerprinting Drug Screening System.
• The Method Comparison Study demonstrated high accuracy (above 98%), sensitivity (above 94%), and perfect specificity (100%) for codeine detection.
• Usability studies confirmed the system can be easily administered by operators without specialized knowledge, making it suitable for workplace use.
• Interference studies showed that common everyday substances do not impact the system's accuracy or specificity.
• Precision testing across multiple sites and production runs confirmed repeatable and reproducible performance.
• Cybersecurity and software documentation were addressed, with all identified vulnerabilities remediated and verified by third parties.
• The submission represents a significant step towards entering the multi-billion dollar U.S. drug screening market.
• The system is already commercially deployed in certain countries outside the U.S. across various settings.

Negatives

• FDA clearance is still pending, and there is no guarantee of approval.
• The filing does not provide specific financial details related to the cost of the clinical studies or the expected revenue from U.S. market entry.

Risks

• Regulatory approval from the FDA is not guaranteed and may be subject to further review or requirements.
• Competition within the multi-billion dollar U.S. drug screening market is significant.
• The company's ability to successfully commercialize the system in the U.S. market post-clearance is subject to market adoption and sales execution.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.

Future Outlook

FDA clearance is expected to expand the Company's addressable market beyond Forensic Use Only settings, supporting its broader U.S. commercialization strategy. The company has confidence in its 510(k) package and its ability to enter the U.S. market.

Management Comments

• "For the past 12 months, planning and executing the studies to build a strong body of data to support our submission has been our teams primary goal," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions.
• "All of this hard work is reflected in our results, and we have great confidence in our 510(k) package."

Industry Context

StockSavvy.ai notes that the submission aligns with the growing demand for rapid, non-invasive drug screening solutions in the U.S. market, particularly in safety-critical industries. The company's focus on opiate detection is timely given the ongoing opioid crisis.

Stakeholder Impact

• Shareholders: Potential for increased market capitalization and revenue if FDA clearance is obtained and U.S. market entry is successful.
• Customers (Employers): Access to a new, potentially more accurate and efficient drug screening tool for workplace safety.
• Regulatory Bodies (FDA): Review of the submitted data to ensure the system meets safety and efficacy standards.

Next Steps

• Await FDA review and potential clearance of the 510(k) premarket notification.
• Expand commercialization strategy in the U.S. market upon receiving FDA clearance.
• Leverage existing deployments in countries outside the U.S. to support U.S. market entry.

Key Dates

Recommendation

The filing represents a significant step towards U.S. market entry, which is positive. However, FDA clearance is still pending, and the actual market performance is yet to be seen. Therefore, a 'hold' recommendation is appropriate pending further developments.

Keywords

drug screening, FDA submission, 510(k), opiate detection, Intelligent Fingerprinting, medical technology, codeine, clinical study